This summary was created by AI, based on 1 opinions in the last 12 months.
Arbutus Biopharma (ABUS-Q) is viewed with skepticism by experts in the investment community. The prevailing sentiment is that the company is facing challenges, primarily related to its financial performance, as it is reportedly losing money. Currently priced at $3, experts describe investing in Arbutus as akin to gambling, likening the stock to a casino where uncertainty prevails. This assessment suggests that potential investors should exercise caution and thoroughly evaluate their risk tolerance before considering an investment in this biotechnology stock. The company operates in a highly competitive and volatile sector, which may further complicate its financial recovery and future prospects.
He has to be careful, because one drug could be a home run, but he has stayed away because it is so hard to predict how drugs will do through the whole approval process. You get a product that looks very promising through the first few stages of testing and trials. Right at the end, when they do the large scale trials, something turns up that hasn’t been seen in the smaller trials. To bring a new drug through the approval process is upwards of $1 billion. Because of this, they usually end up partnering with a big Pharma, and the value goes to the big Pharma.
A play on ebola could have a nice kick up now, but looking at the financials, they have lost money in 8 out of the last 10 years. This does not bode well. Also, they are not at all close to getting the product into the market. The testing for their product was actually for another product, so they are going to have to have a certain amount of latitude in getting it out. He would prefer Alpha Pro Tech (APT-A).
Arbutus Biopharma is a American stock, trading under the symbol ABUS-Q on the NASDAQ (ABUS). It is usually referred to as NASDAQ:ABUS or ABUS-Q
In the last year, 2 stock analysts published opinions about ABUS-Q. 1 analyst recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Arbutus Biopharma.
Arbutus Biopharma was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Arbutus Biopharma.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
In the last year, there was no coverage of Arbutus Biopharma published on Stockchase.
On 2025-04-01, Arbutus Biopharma (ABUS-Q) stock closed at a price of $3.48.
The ultimate spec. It loses money. Now at $3. A casino.